CA2943871C - POXVIRAL ONCOLYTIC VECTORS - Google Patents

POXVIRAL ONCOLYTIC VECTORS

Info

Publication number
CA2943871C
CA2943871C CA2943871A CA2943871A CA2943871C CA 2943871 C CA2943871 C CA 2943871C CA 2943871 A CA2943871 A CA 2943871A CA 2943871 A CA2943871 A CA 2943871A CA 2943871 C CA2943871 C CA 2943871C
Authority
CA
Canada
Prior art keywords
oncolytic vectors
poxviral
poxviral oncolytic
vectors
compsositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2943871A
Other languages
English (en)
French (fr)
Other versions
CA2943871A1 (en
Inventor
Philippe Erbs
Johann Foloppe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transgene SA
Original Assignee
Transgene SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/249,713 external-priority patent/US9687515B2/en
Application filed by Transgene SA filed Critical Transgene SA
Publication of CA2943871A1 publication Critical patent/CA2943871A1/en
Application granted granted Critical
Publication of CA2943871C publication Critical patent/CA2943871C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2943871A 2014-04-10 2015-04-09 POXVIRAL ONCOLYTIC VECTORS Active CA2943871C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/249,713 US9687515B2 (en) 2007-11-19 2014-04-10 Poxviral oncolytic vectors
US14/249,713 2014-04-10
PCT/EP2015/057654 WO2015155263A1 (en) 2014-04-10 2015-04-09 Poxviral oncolytic vectors

Publications (2)

Publication Number Publication Date
CA2943871A1 CA2943871A1 (en) 2015-10-15
CA2943871C true CA2943871C (en) 2025-05-06

Family

ID=53051793

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2943871A Active CA2943871C (en) 2014-04-10 2015-04-09 POXVIRAL ONCOLYTIC VECTORS

Country Status (10)

Country Link
EP (1) EP3129037B1 (OSRAM)
JP (1) JP6657115B2 (OSRAM)
KR (1) KR102457060B1 (OSRAM)
CN (1) CN106413726B (OSRAM)
AU (1) AU2015243297B2 (OSRAM)
CA (1) CA2943871C (OSRAM)
DK (1) DK3129037T3 (OSRAM)
ES (1) ES2768715T3 (OSRAM)
IL (1) IL247535B (OSRAM)
WO (1) WO2015155263A1 (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018091680A1 (en) * 2016-11-18 2018-05-24 Transgene Sa Cowpox-based oncolytic vectors
EP3610870A4 (en) * 2017-03-31 2020-12-09 Ogata, Hisanobu METHOD OF EXPANSION OF AN ONCOLYTIC VIRUS AND ANTI-TUMOR AGENT
IL284421B2 (en) * 2018-12-28 2025-05-01 Transgene M2-defective poxvirus
CN110747174A (zh) * 2019-10-30 2020-02-04 青岛宁逸生物科技有限公司 一种用于肿瘤治疗的重组病毒

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364773A (en) 1991-03-07 1994-11-15 Virogenetics Corporation Genetically engineered vaccine strain
AU672359B2 (en) * 1991-03-07 1996-10-03 Virogenetics Corporation Genetically engineered vaccine strain
US5358866A (en) 1991-07-03 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Cytosine deaminase negative selection system for gene transfer techniques and therapies
US5856153A (en) 1994-11-17 1999-01-05 Cayla Suicide genes and new associations of pyrimidine nucleobase and nucleoside analogs with new suicide genes for gene therapy of acquired diseases
FR2777570A1 (fr) 1998-04-17 1999-10-22 Transgene Sa Mutant ayant une activite phosphoribosyl transferase
EP1180157B1 (en) * 1999-05-28 2012-11-28 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES A combined growth factor-deleted and thymidine kinase-deleted vaccinia virus vector
AU2003258168B2 (en) 2002-08-12 2009-10-29 Sillajen Biotherapeutics, Inc. Methods and compositions concerning poxviruses and cancer
KR101062140B1 (ko) 2003-07-21 2011-09-05 트랜스진 에스.에이. 향상된 시토신 디아미네이즈 활성을 갖는 폴리펩티드
DE602005012535D1 (de) 2004-11-08 2009-03-12 Transgene Sa Aus teilen bestehendes kit für die durchführung einer antitumorbehandlung oder antiviralen behandlung in einem säugetier
KR20080084528A (ko) * 2007-03-15 2008-09-19 제네렉스 바이오테라퓨틱스 인크. 종양살상형 백시니아 바이러스 암 치료
CA2693623A1 (en) * 2007-07-18 2009-01-22 Genelux Corporation Use of a chemotherapeutic agent in the preparation of a medicament for treating or ameliorating an adverse side effect associated with oncolytic viral therapy
BRPI0820576B1 (pt) * 2007-11-19 2021-10-19 Transgène S.A. Uso de um poxvírus oncolítico compreendendo um gene i4l e/ou f4l defectivo ou uma composição compreendendo o mesmo
US20100173013A1 (en) * 2009-01-08 2010-07-08 Denis Drygin Treatment of neoplastic disorders using combination therapies
CA2709292A1 (en) * 2009-07-10 2011-01-10 The Governors Of The University Of Alberta Oncolytic viruses and methods for treating neoplastic disorders

Also Published As

Publication number Publication date
AU2015243297B2 (en) 2020-10-15
CA2943871A1 (en) 2015-10-15
KR102457060B1 (ko) 2022-10-19
AU2015243297A1 (en) 2016-09-29
JP6657115B2 (ja) 2020-03-04
ES2768715T3 (es) 2020-06-23
AU2015243297A2 (en) 2016-09-29
IL247535A0 (en) 2016-11-30
CN106413726B (zh) 2020-07-24
WO2015155263A1 (en) 2015-10-15
JP2017515806A (ja) 2017-06-15
EP3129037A1 (en) 2017-02-15
IL247535B (en) 2019-05-30
CN106413726A (zh) 2017-02-15
DK3129037T3 (da) 2020-02-03
KR20160145058A (ko) 2016-12-19
EP3129037B1 (en) 2019-11-13

Similar Documents

Publication Publication Date Title
ZA202004557B (en) Modulatory polynucleotides
MX2021006581A (es) Bacterias modificadas para tratar enfermedades asociadas con hiperamonemia.
EP3166640A4 (en) Combination therapy compositions and methods for treating cancers
MY187540A (en) Compounds active towards bromodomains
IL253979B (en) Methods, preparations and kits for cancer treatment
TW201611847A (en) Compounds and compositions for treating EGFR expressing tumors
EA201992251A1 (ru) Противораковые вакцины и способы лечения с их применением
GB2541571A (en) Pharmaceutical compositions
HK1248588A1 (zh) 用於癌症治疗中的天花疫苗
IL254103A0 (en) Compositions and methods for increasing the effectiveness of cancer treatment
AU2016246521A8 (en) Treatment of lung cancer with inhibitors of glutaminase
MX2018002344A (es) Metodo para tratar el cancer.
EP3256110A4 (en) Compositions and methods of tumor treatment utilizing nanoparticles
WO2017079570A3 (en) Splise-switching oligonucleotides and methods of use
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
MX379271B (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cáncer.
IL254842B (en) Therapeutic preparations and methods for use in cancer treatment
MX2017006026A (es) Apilimod para uso en el tratamiento de cancer colorrectal.
JO3541B1 (ar) علاجات طبية قائمة على اناموريلين
MX379622B (es) Compuestos espirociclicos
MX2016009655A (es) Metodos novedosos para el tratamiento del cancer.
PH12016501838A1 (en) Compounds and their methods of use
CA2943871C (en) POXVIRAL ONCOLYTIC VECTORS
MX2019004804A (es) Tratamiento para el prurigo nodula.

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200408

EEER Examination request

Effective date: 20200408

EEER Examination request

Effective date: 20200408

EEER Examination request

Effective date: 20200408

EEER Examination request

Effective date: 20200408

EEER Examination request

Effective date: 20200408

EEER Examination request

Effective date: 20200408

EEER Examination request

Effective date: 20200408

EEER Examination request

Effective date: 20200408